Antiretroviral therapy in relation to birth outcomes among HIV-infected women: A cohort study

Journal of Infectious Diseases

Volumn 213, Issue 7, 2016, Pages 1057-1064

  Li, Nan ^a   Sando, Mary Mwanyika ^b   Spiegelman, Donna ^a   Hertzmark, Ellen ^a   Liu, Enju ^a   Sando, David ^b   MacHumi, Lameck ^b   Chalamilla, Guerino ^b   Fawzi, Wafaie ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MANAGEMENT AND DEVELOPMENT FOR HEALTH   (Tanzania)

Author keywords

Africa; Antiretroviral therapy; Birth outcome; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMALL FOR DATE INFANT; TANZANIA; ADVERSE EFFECTS; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED; CLINICAL TRIAL; EPIDEMIOLOGY; GESTATIONAL AGE; HIV INFECTIONS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURITY; STATISTICAL MODEL; TRANSMISSION; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREMATURE BIRTH; PROSPECTIVE STUDIES; TANZANIA; YOUNG ADULT;

EID: 84962494626     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv389     Document Type: Article

References (48)

1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2013:v.
2. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-82.
3. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach-2010 version. Geneva: World Health Organization, 2010.
4. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach June 2013. Geneva, Switzerland: World Health Organization, 2013.
5. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva, Switzerland: World Health Organization, 2014.
6. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother- to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-80.
7. Li N, Matchi E, Spiegelman D, et al. Maternal mortality among HIV-infected pregnant women in Tanzania. Acta Obstet Gynecol Scand 2014; 93:463-8.
8. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants Programmatic update. Geneva, Switzerland: World Health Organization, 2012.
9. Meeting Report: Beyond Option B+. Switzerland: International AIDS Society, 2013.
10. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-705.
11. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20:2345-53.
12. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS 2011; 25:1611-8.
13. Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 2012; 26:37-43.
14. Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancy outcome in HIV-1- infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 2007; 114:148-55.
15. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single-center cohort study. J Infect Dis 2007; 196:558-61.
16. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348-60.
17. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-26.
18. Yu L, Li WY, Chen RY, et al. Pregnancy outcomes and risk factors for low birth weight and preterm delivery among HIV-infected pregnant women in Guangxi, China. Chin Med J (Engl) 2012; 125:403-9.
19. Dola CP, Khan R, DeNicola N, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 2011; 40:51-5.
20. Aaron E, Bonacquisti A, Mathew L, Alleyne G, Bamford LP, Culhane JF. Small-forgestational- age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy. Infect Dis Obstet Gynecol 2012; doi:10.1155/2012/135030.
21. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Abridged ed. Champaign, Ill Human Kinetics Books, 1991.
22. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003; 3:6.
23. Dim CC, Onah HE. The prevalence of anemia among pregnant women at booking in Enugu, South Eastern Nigeria. Med Gen Med 2007; 9:11.
24. Baig-Ansari N, Badruddin SH, Karmaliani R, et al. Anemia prevalence and risk factors in pregnant women in an urban area of Pakistan. Food Nutr Bull 2008; 29:132-9.
25. Nagu T, Kanyangarara M, Hawkins C, et al. Elevated alanine aminotransferase in antiretroviral-naive HIV-infected African patients: magnitude and risk factors. HIV Med 2012; 13:541-8.
26. WHO. 10 Facts on obesity: BMI classification. http://www.who.int/features/factfiles/obesity/facts/en/. Accessed 3 August 2015.
27. Papathakis P, Rollins N. HIV and nutrition: pregnant and lactating women. Durban, South Africa: World Health Organization, 2005.
28. Ribowsky J, Henderson C. Pregnancy-induced hypertension. Clin Rev 2012; 22:27-32.
29. Miettinen OS. Theoretical epidemiology: principles of occurrence research in medicine. New York: Wiley, 1985 A Wiley medical publication).
30. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551-61.
31. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA. Comparing smoothing techniques in Cox models for exposure-response relationships. Stat Med 2007; 26:3735-52.
32. van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc 2011; 14:42.
33. Short CE, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med 2014; 15:233-8.
34. Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1- infected women. HIV Med 2008; 9:6-13.
35. Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195:913-4; author reply 6-7.
36. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 2008; 22:1815-20.
37. Fowler M, Qin M, Shapiro D, et al. PROMISE: Efficacy and safety of 2 strategies to prevent perinatal HIV transmission. In: CROI. Seattle, Washington, 2015.
38. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-7.
39. van der Merwe K, Chersich M, Black V, Technau K, Rees H, Coovadia A. The impact of in-utero antiretroviral therapy (ART) exposure on infant outcomes in Johannesburg. In: South Africa 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 2009.
40. Ekouevi DK, Coffie PA, Ouattara E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEAWest Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2011; 56:183-7.
41. Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 2007; 45:269-73.
42. Use of efavirenz during pregnancy: a public health perspective. Geneva, Switzerland: WHO, 2012.
43. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. Am J Reprod Immunol 2006; 70:143-50.
44. Short CE, Taylor GP. Antiretroviral therapy and preterm birth in HIV-infected women. Expert Rev Anti Infect Ther 2014; 12:293-306.
45. Shapiro RL, Souda S, Parekh N, et al. High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in Botswana. PLOS One 2012; 7:e31580.
46. Papp E, Loutfy M, Yudin M. Angiogenesis and Adverse Pregnancy Outcomes in Women with HIV: The AAPH Study. In: 3rd International Conference on HIV and Women. Toronto, Canada, 2013.
47. Rosenberg RE, Ahmed AS, Ahmed S, et al. Determining gestational age in a lowresource setting: validity of last menstrual period. J Health Popul Nutr 2009; 27:332-8.
48. European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-20.